» Articles » PMID: 12393814

Bacterial Redox Protein Azurin, Tumor Suppressor Protein P53, and Regression of Cancer

Overview
Specialty Science
Date 2002 Oct 24
PMID 12393814
Citations 55
Authors
Affiliations
Soon will be listed here.
Abstract

The use of live bacteria in the treatment of cancer has a long and interesting history. We report the use of a purified bacterial redox protein, azurin, that enters human cancer (melanoma UISO-Mel-2) cells and induces apoptosis. The induction of apoptosis occurs readily in melanoma cells harboring a functional tumor suppressor protein p53, but much less efficiently in p53-null mutant melanoma (UISO-Mel-6) cells. A redox-negative mutant form of azurin (M44K/M64E) demonstrates much less cytotoxicity to the UISO-Mel-2 cells than the wild-type protein. Azurin has been shown to be internalized in UISO-Mel-2 cells and is localized predominantly in the cytosol and in the nuclear fraction. In the p53-null UISO-Mel-6 cells, azurin is localized only in the cytosol. Thus, intracellular trafficking of azurin to the nucleus is p53-dependent. Azurin forms a complex with p53, thereby stabilizing it and raising its intracellular level in cytosolic, mitochondrial, and nuclear fractions. Corresponding to an increasing level of p53, an inducer of apoptosis, the level of Bax also increases in mitochondria, allowing significant release of mitochondrial cytochrome c into the cytosol, thus initiating the onset of apoptosis. The M44K/M64E mutant form of azurin, deficient in cytotoxicity, is also deficient in forming a complex with p53 and is less efficient in stabilizing p53 than wild-type azurin. Azurin has been shown to allow regression of human UISO-Mel-2 tumors xenotransplanted in nude mice and may potentially be used in cancer treatment.

Citing Articles

PeptiHub: a curated repository of precisely annotated cancer-related peptides with advanced utilities for peptide exploration and discovery.

Zareei S, Khorsand B, Dantism A, Zareei N, Asgharzadeh F, Zahraee S Database (Oxford). 2024; 2024.

PMID: 39308247 PMC: 11417155. DOI: 10.1093/database/baae092.


Bacteriocins in Cancer Treatment: Mechanisms and Clinical Potentials.

Wang Y, Wang Y, Sun T, Xu J Biomolecules. 2024; 14(7).

PMID: 39062544 PMC: 11274894. DOI: 10.3390/biom14070831.


Multi-omics differences in the bone marrow between essential thrombocythemia and prefibrotic primary myelofibrosis.

Zhang A, Sun T, Yu D, Fu R, Liu X, Xue F Clin Exp Med. 2024; 24(1):154.

PMID: 38972952 PMC: 11228008. DOI: 10.1007/s10238-024-01350-y.


Redefining bioactive small molecules from microbial metabolites as revolutionary anticancer agents.

Giurini E, Godla A, Gupta K Cancer Gene Ther. 2024; 31(2):187-206.

PMID: 38200347 PMC: 10874892. DOI: 10.1038/s41417-023-00715-x.


Peptide-Based Agents for Cancer Treatment: Current Applications and Future Directions.

Nhan N, Yamada T, Yamada K Int J Mol Sci. 2023; 24(16).

PMID: 37629112 PMC: 10454368. DOI: 10.3390/ijms241612931.


References
1.
Reed J . Dysregulation of apoptosis in cancer. J Clin Oncol. 1999; 17(9):2941-53. DOI: 10.1200/JCO.1999.17.9.2941. View

2.
Maki C . Oligomerization is required for p53 to be efficiently ubiquitinated by MDM2. J Biol Chem. 1999; 274(23):16531-5. DOI: 10.1074/jbc.274.23.16531. View

3.
Kirn D . Replication-selective microbiological agents: fighting cancer with targeted germ warfare. J Clin Invest. 2000; 105(7):837-9. PMC: 377493. DOI: 10.1172/JCI9761. View

4.
Marchenko N, Zaika A, Moll U . Death signal-induced localization of p53 protein to mitochondria. A potential role in apoptotic signaling. J Biol Chem. 2000; 275(21):16202-12. DOI: 10.1074/jbc.275.21.16202. View

5.
Farver O, Jeuken L, Canters G, Pecht I . Role of ligand substitution on long-range electron transfer in azurins. Eur J Biochem. 2000; 267(11):3123-9. DOI: 10.1046/j.1432-1327.2000.01317.x. View